Ask AI
ProCE Banner Series

Expert Roundtable on the Current and Near Future Impact of Novel Therapeutic Options for Relapsed/Refractory CLL/SLL

Join us for a live webinar after the conclusion of the International Workshop on CLL and hear experts discuss the latest updates on novel therapeutic options for relapsed/refractory CLL/SLL, including CAR T-cell therapy and noncovalent BTK inhibitors, and the current and potential impact on clinical practice.

To Register: Please click the green “Learn More” button below. On the next page, select Register for Virtual Event. Once registered, you will receive a confirmation email. Follow-up emails with event details will be sent as the event nears.

  AMA
Who Should Attend

This program is intended for hematologists, oncologists, and other healthcare professionals who care for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

All Events

Expert Roundtable on the Current and Near Future Impact of Novel Therapeutic Options for Relapsed/Refractory CLL/SLL

Past Events

November

09

2023

12:00 PM - 1:00 PM Eastern Time (ET)

Virtual

Topics

Welcome and Program Overview

Overview of Current Treatment for R/R CLL/SLL

Novel BTK Inhibitors for R/R CLL/SLL

Identifying and Managing BTK Inhibitor–Associated Toxicities

Emerging Role of CAR T-Cell Therapy in CLL/SLL

Key Points With CAR T-Cell Therapy Toxicity in CLL/SLL

Final Thoughts and Audience Question and Answer Session

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Chronic Lymphocytic Leukemia (CLL)

Target Audience
This program is intended for hematologists, oncologists, and other healthcare professionals who care for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate the available evidence and expected clinical role of emerging CAR T-cell and BTKi therapies in R/R CLL/SLL
  • Plan individualized therapeutic strategies to optimize integration and sequencing of CAR T-cell therapies and noncovalent BTKis for patients with R/R CLL/SLL, including patient selection, referral to specialized CAR T-cell treatment centers, patient care coordination, and pretreatment/posttreatment supportive care
  • Implement proactive strategies for monitoring and managing toxicities associated with CAR T-cell therapies and noncovalent BTKis in patients with R/R CLL/SLL
  • Appraise ongoing clinical trials evaluating CAR T-cell therapy and noncovalent BTKis for the treatment of patients with CLL/SLL for appropriate and inclusive patient enrollment

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by educational grants from Lilly and Merck Sharp & Dohme LLC.

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191